Should isosorbide mononitrate be continued beyond one year after angioplasty (percutaneous coronary intervention) in a stable adult patient?

Should Isosorbide Mononitrate Be Continued After One Year Post-Angioplasty?

No, isosorbide mononitrate should generally be discontinued or significantly reduced after successful angioplasty in stable patients who are symptom-free, as current guidelines do not recommend long-acting nitrates for routine secondary prevention after revascularization, and evidence shows they may actually impair endothelial function with long-term use.

Guideline-Based Approach

The 2024 ESC guidelines for chronic coronary syndromes provide clear direction on nitrate use 1:

• Short-acting nitrates are recommended for immediate relief of angina (as-needed basis)
• Long-acting nitrates are NOT listed among first-line antianginal therapy - the guidelines recommend beta-blockers and/or calcium channel blockers as initial treatment for most CCS patients
• Nitrates are specifically contraindicated in certain conditions (hypertrophic cardiomyopathy, concurrent phosphodiesterase inhibitor use)

The 2021 ACC/AHA/SCAI revascularization guidelines 2 focus on antithrombotic therapy post-PCI but notably do not recommend routine continuation of long-acting nitrates for secondary prevention after successful revascularization.

Evidence Against Long-Term Continuation

Endothelial Dysfunction

Long-term isosorbide mononitrate treatment actively impairs endothelial function in CAD patients. A randomized controlled trial showed that after 1 year of ISMN treatment, flow-mediated dilation (FMD) decreased significantly from 5.97% to 5.33%, while the placebo group improved from 6.27% to 6.96% (P=0.006) 3. This represents actual harm from continued therapy.

Tolerance Development

The FDA label explicitly warns that tolerance develops with continuous nitrate exposure 4. Studies show that even with extended-release formulations, effects diminish over time - at 42 days, the antianginal effects were "less than or at best equal to the effects of the first dose" 4.

Lack of Symptom-Driven Need

Research demonstrates that 87% of patients remain free of MI, CABG, or repeat intervention at 6 months post-PCI, with 69% completely angina-free 5. Despite this marked improvement, 36% continued nitrates unnecessarily 5, suggesting clinical inertia rather than medical necessity drives continuation.

Clinical Decision Algorithm

Assess at 1-year post-angioplasty:

1. If completely asymptomatic with no angina:

   • Discontinue isosorbide mononitrate
   • Provide short-acting nitroglycerin for breakthrough symptoms only
   • Continue evidence-based secondary prevention (aspirin, statin, beta-blocker if prior MI)

2. If residual angina present:

   • First optimize beta-blockers and/or calcium channel blockers per guidelines 1
   • Consider adding ranolazine or ivabradine before continuing long-acting nitrates
   • If nitrates needed, use once-daily dosing to allow nitrate-free interval (prevents tolerance) 6

3. If recurrent symptoms develop:

   • Evaluate for restenosis or disease progression before simply continuing nitrates
   • Consider stress testing or coronary imaging

Key Caveats

Absolute contraindications to continuing nitrates:

• Concurrent use of phosphodiesterase-5 inhibitors (sildenafil, tadalafil) - risk of severe hypotension 1, 4
• Hypertrophic cardiomyopathy 1
• Severe hypotension or volume depletion 4

Common pitfall: Clinicians often continue medications started peri-procedurally without reassessing need. The ORBITA trial showed that while optimal medical therapy can be achieved, isosorbide mononitrate and nicorandil had the highest discontinuation rates for adverse effects (20.9% and 22.7% respectively) 7, suggesting poor long-term tolerability.

Special consideration: In heart failure with preserved ejection fraction, isosorbide mononitrate actually decreased daily activity levels and hours of activity per day compared to placebo, with no improvement in quality of life 8. This reinforces that nitrates should not be continued without clear symptomatic benefit.

Secondary Prevention Focus

Instead of continuing isosorbide mononitrate, ensure these evidence-based therapies:

• Aspirin 75-100 mg daily (lifelong) 1
• High-intensity statin targeting LDL-C <55 mg/dL 1
• Beta-blocker if prior MI
• ACE inhibitor/ARB if indicated
• Aggressive risk factor modification (exercise, smoking cessation, diabetes control)

The evidence strongly supports discontinuing routine long-acting nitrate therapy after successful revascularization in stable, asymptomatic patients, reserving short-acting nitrates for breakthrough symptoms only.